Immunovant

IMVTNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$5.873 B

$28.44 -4.90%

Close of 6 Nov 2026

As of 6 Nov 2026, Immunovant (IMVT) has a market capitalization of $5.87B. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

—

Not reported

Earnings

-$505.6M

Loss-making

Shares outstanding

206,552,682

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →

#17ImmunityBioIBRX$8.48B
#18Twist BioscienceTWST$7.95B
#19ImmunovantIMVT$5.87B
#20CG OncologyCGON$5.74B
#21Kodiak SciencesKOD$5.73B

What if Immunovant were worth as much as…

Open the what-if tool →

Gold $28.2T

$136,705.43

Per share 4,808× higher

Bitcoin $1.53T

$7,396.89

Per share 260× higher

Apple $5.02T

$24,283.31

Per share 854× higher

Or at a round number

$10.0B $20.0B $50.0B $100.0B

Where these numbers come from

Share counts and financials for Immunovant are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.